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hematologic disease.1,2 Solid tumors are rarely affected by
tumor lysis syndrome because they are relatively resistant
to cytotoxic therapies. Mortality rate in patients with solid
tumors is higher because of delayed diagnosis.2 A 51-year-
old man with chronic hepatitis B was admitted for large
hepatocellular carcinoma (HCC). Abdominal computed
tomography showed liver cirrhosis and a 17-cm hepatic
tumor at S7/S8 with contrast enhancement in the arterial
phase and washout in the venous phase. No evidence of
portal vein thrombosis was noted. Abdominal magnetic
resonance imaging showed similar results. Preoperative
portal venous embolization (PVE)3 and transarterial che-
moembolization (TACE) were used to decrease the tumor
burden. Two days after TACE, elevation of aminotrans-
ferase, bilirubin, uric acid, creatinine, and lactic dehy-
drogenase levels were noted (Table 1). Tumor lysis
syndrome with acute kidney injury was diagnosed. 2,4 Renal
and liver function gradually improved after adequate
hydration and rasburicase administration. Left lobe hyper-
trophy after PVE was observed; however, the volume of left* Corresponding author. Department of Internal Medicine,
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further sessions of TACE were performed for the residual
tumor without recurrence of tumor lysis syndrome. The
patient was followed up at an outpatient clinic. The
common risk factors for tumor lysis syndrome are tumor
burden, cancer lysis potential, baseline renal insufficiency,
dehydration, hyperuricemia, hypotension, and exposure to
nephrotoxins. In previous case reports about TACE-induced
tumor lysis syndrome,5 a large tumor burden (>5 cm) is the
common feature. In this case, PVE and large tumor burden
led to increased tumor necrosis and subsequent tumor lysis
syndrome. When tumor lysis syndrome develops, treatment
with aggressive hydration, allopurinol, rasburicase, and
urine alkalinization is warranted.1,2 Aggressive hydration
can rapidly improve renal perfusion and glomerular filtra-
tion and minimize acidosis. Loop diuretics can be used to
maintain adequate urine output. Rasburicase is more
effective than allopurinol in preventing xanthine accumu-
lation and directly breaking down uric acid. Urine alkalin-
ization can be considered when rasburicase is not available,
but it must be discontinued when hyperphosphatasemia
develops. In addition, electrolyte, creatinine, and uric acid
levels should be monitored frequently (every 4e6 hours in
high-risk groups). Tumor lysis syndrome is not normally
considered among the complications of TACE because of its
low incidence. Thus, mortality rates are high because of
delayed diagnosis. With early detection and treatment, our& Formosan Medical Association. All rights reserved.
Table 1 Serial laboratory data before and after TACE.
Reference range Baseline After PVE After TACE
3 d 2 d 4 d 9 d 12 d 15 d 42 d 80 d
AST <37 U/L 71 73 9349 486 52 64 46
ALT <41 U/L 60 61 691 169 46 50 27
T-bil 0.2e1.2 mg/dL 1.1 1.3 7.1 7.8 8.4 4.5 3.8 1.5 1.0
BUN 4.5e24 mg/dL 21 42 73 135 123 79 20 20
Cr 0.6e1.3 mg/dL 1.3 4.1 7.5 5.4 3.6 2.6 1.6 1.5
Na 135e148 mmol/L 135 121 126 133 133 133
K 3.5e5.3 mmol/L 4.2 4.4 3.9 4.8 4.3
Ca 2.02e2.6 mmol/L 1.86 2.28 2.3
P 2.7e4.5 mg/dL 7.2 7.6 3.1 3.2
UA 3.5e7.5 mg/dL 15.5 9.2
LDH 230e460 U/L 33820 605 362
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; BUN Z blood urea nitrogen; Ca Z calcium; Cr Z creatinine;
KZ potassium; LDHZ lactic dehydrogenase; NaZ sodium; PZ phosphate; PVEZ portal venous embolization; T-bilZ total bilirubin;
TACE Z transarterial chemoembolization; UA Z uric acid.
Tumor lysis syndrome in HCC 725patient recovered without incident. Therefore, tumor lysis
syndrome must be considered in patients undergoing TACE
for HCC. Early detection and intervention can reduce
mortality rates because of tumor lysis syndrome.
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